This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVO

About ABRYSVO

Efficacy ProfileImmunobridgingSafety ProfileDosing, Storage, & ReconstitutionPatient ProfilesOrder ABRYSVOAccess & Support

Access & Support

Health Plan CoverageRequest a RepVaccine LocatorEventsMaterialsVideos
Prescribing InformationIndicationsPatient SiteMaternal
Every Breath Matters.
Discuss vaccination today with older adults. Don't wait.
ABRYSVO®: CDC-recommended as a single dose for all adults aged 75 and older and for adults 60-74 years who are at increased risk of severe RSV disease1,2*
ABRYSVO®: CDC-recommended as a single dose for all adults aged 75 and older and for adults 60-74 years who are at increased risk of severe RSV disease1,2*
 View the Clinical Data Loading View CDC Recommendation Loading View the Clinical Data Loading View CDC Recommendation Loading
CDC-recommended as a single dose for all adults aged 75 and older and for adults 60 to 74 years who are at increased risk of severe RSV disease2,3*
CDC-recommended as a single dose for all adults aged 75 and older and for adults 60 to 74 years who are at increased risk of severe RSV disease2,3*
ReferencesRSV vaccination should only be given to adults who have not yet received a dose of RSV vaccine. Providers can give the RSV vaccine year-round. However, RSV vaccination will have the most benefit if given in late summer or early fall.3 Powerful protection against RSV in adults 60 years and older†

86% vaccine efficacy against RSV-LRTD with ≥3 symptoms
(96.66% CI: 32.0, 98.7)1

67% vaccine efficacy against RSV-LRTD with ≥2 symptoms
(96.66% CI: 28.8, 85.8)1

 View Efficacy Data

†Primary Analysis: The median duration of efficacy follow-up was 7 months. Evaluable efficacy population: ABRYSVO, n=16,306; placebo, n=16,308.1

 Rates of systemic AEs similar to placebo in older adults Similar rate of systemic events reported between ABRYSVO (27%) and placebo (26%) groups1

The most commonly reported solicited local and systemic adverse reactions in individuals 60 years of age and older (≥10%) with ABRYSVO were fatigue (15.7%), headache (12.9%), pain at the injection site (10.7%), and muscle pain (10.2%)1 View Safety Data Loading
Take every opportunity to vaccinate this RSV season1,2
Vaccinate your eligible patients aged 60 years and older today with ABRYSVO1 Vaccine Locator Tool LoadingApproved for 3 Vulnerable Populations

ABRYSVO: 1 vaccine approved to prevent RSV-LRTD in1: 

  • Adults aged 18-59 at increased risk  
  • Adults aged 60+
  • Infants from birth through 6 months of age via maternal immunization (given at 32-36 weeks of gestation) 

Learn more about the maternal indication

LoadingABRYSVO Reconstitution Options

ABRYSVO offers 2 needle-free‡ options to fit your practice

Learn more about ABRYSVO® ACT-O-VIAL® and the ABRYSVO® Reconstitution Kit

‡Needle required for intramuscular injection is not included.

LoadingResources and Access Info

Get the support you need and learn more about costs and coverage

LoadingAE=adverse event; CDC=Centers for Disease Control and Prevention; CI=confidence interval; LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus.
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

 View ResourcesLoading
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View ResourcesLoading
References:ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; October 2024. Centers for Disease Control and Prevention. CDC updates RSV vaccination recommendation for adults. Published June 26, 2024. Accessed July 3, 2024. https://www.cdc.gov/media/releases/2024/s-0626-vaccination-adults.htmlMelgar M, Britton A. ACIP adult RSV work group clinical considerations. Centers for Disease Control and Prevention. Published June 26, 2024. https://www.cdc.gov/acip/downloads/slides-2024-06-26-28/12-RSV-Adult-Melgar-508.pdf

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-A1G-USA-1772
IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all vaccine recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions
were fatigue (15.7%), headache (12.9%), pain at the injection site (10.7%), and muscle pain (10.2%)
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions
were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO versus 4.4% placebo) and neonatal jaundice (7.2% ABRYSVO versus 6.7% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO.IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
     
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
You are now leaving PfizerPro  
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367